Haematology

News

Under pressure, Novo lays out blockbuster launch plans

Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.

News

Hengrui gets world-first okay for platelet drug hetrombopag

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

News

AbbVie's cancer TCE etentamig hits the mark in myeloma

AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

News

Agios shares slide as it abandons sickle cell candidate

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

Under pressure, Novo lays out blockbuster launch plans

Hengrui gets world-first okay for platelet drug hetrombopag

AbbVie's cancer TCE etentamig hits the mark in myeloma

FDA clears Takeda, Protagonist's first-in-class PV drug

Agios shares slide as it abandons sickle cell candidate

Brukinsa data raises chemo-free hope for mantle cell lymphom...

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

Haematology

Editor's Picks